Acceleron Ends ACE-083 FSHD Testing After Phase II Failure
Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.
You may also be interested in...
The ReDUX4 study missed its biomarker-driven primary endpoint, making it unclear if an additional trial will be needed for regulatory submission.
Top-line Phase II results from the PULSAR study suggest Acceleron’s sotatercept is effective as add-on treatment for patients with PAH, and could be a new class of therapy for a still difficult-to-control condition.
The latest drug development news and highlights from our US FDA Performance Tracker.